Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H30N6O2S |
| Molecular Weight | 442.578 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C1=C(SC2=NC3=C(N)N=CC=C3N2CCNCC(C)(C)C)C=C4OCOC4=C1
InChI
InChIKey=RVJIQAYFTOPTKK-UHFFFAOYSA-N
InChI=1S/C22H30N6O2S/c1-22(2,3)12-24-8-9-28-14-6-7-25-20(23)19(14)26-21(28)31-18-11-17-16(29-13-30-17)10-15(18)27(4)5/h6-7,10-11,24H,8-9,12-13H2,1-5H3,(H2,23,25)
| Molecular Formula | C22H30N6O2S |
| Molecular Weight | 442.578 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19509149
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19509149
CUDC-305, is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents. In both laboratory and animal testing, CUDC-305 demonstrated high potency in vitro and/or in vivo across a wide range of cancers. Most notably, Curis scientists observed complete tumor regression following oral administration of CUDC-305 in a mouse xenograft model of acute myelogenous leukemia (AML). Tumor regression has also been observed after treatment of CUDC-305 in mouse xenograft models of breast, non-small cell lung, gastric cancer and glioblastoma brain cancers. In this preclinical testing, the compound also demonstrated an ability to effectively cross the blood brain barrier, and demonstrated an ability to extend survival in an intracranial glioblastoma model. Early stage toxicity studies suggest that CUDC-305 appears to have a better therapeutic window than several leading Hsp90 inhibitors in clinical development.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.96 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
50 mg 1 times / 2 days multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
27.12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
100 mg 1 times / 2 days multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
26.14 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
200 mg 1 times / 2 days multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
62.45 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
400 mg 1 times / 2 days multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: food status: FASTED |
|
93.37 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
800 mg 1 times / 2 days multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
130.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1600 mg 1 times / 2 days multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.85 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.93 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
81.35 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
82.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
122 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
105.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
178.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
50 mg 1 times / 2 days multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
81.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
100 mg 1 times / 2 days multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
137.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
200 mg 1 times / 2 days multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
466.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
400 mg 1 times / 2 days multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: food status: FASTED |
|
609.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
800 mg 1 times / 2 days multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1137 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1600 mg 1 times / 2 days multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
44.03 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
27.88 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
62.62 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
362.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
711.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1012 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
765.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1181 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
50 mg 1 times / 2 days multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
100 mg 1 times / 2 days multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
200 mg 1 times / 2 days multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
400 mg 1 times / 2 days multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: food status: FASTED |
|
13.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
800 mg 1 times / 2 days multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1600 mg 1 times / 2 days multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.95 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.38 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7.43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25646368/ |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-305 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1600 mg 1 times / day multiple, oral MTD Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
DLT: Diarrhea, Asthenia... Dose limiting toxicities: Diarrhea (33.3%) Sources: Asthenia (33.3%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Asthenia | 33.3% DLT, Disc. AE |
1600 mg 1 times / day multiple, oral MTD Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Diarrhea | 33.3% DLT, Disc. AE |
1600 mg 1 times / day multiple, oral MTD Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Sample Use Guides
Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD. CUDC-305 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:03:30 GMT 2025
by
admin
on
Mon Mar 31 22:03:30 GMT 2025
|
| Record UNII |
0V278OKN9G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CUDC-305
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY | Catalog No. A12648: CUDC-305 (DEBIO-0932)Quick Overview: Debio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents. | ||
|
44156921
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY | |||
|
300000042383
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY | |||
|
DEBIO-0932
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY | Biological Activity of Debio 0932:Debio 0932 (CUDC-305) is a novel heat shock protein 90 (HSP90) inhibitor trong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L).target: HSP90IC50: 220 nmol/Lin vitro: H1993 and H1975 NSCLC cells were incubated with 1 .MU.mol/L CUDC-305 for 7 hours and then cultured in compound-free medium for an additional 0, 17, or 24 hours, respectively, before being analyzed by Western blotin vivo: CUDC-305 was delivered through oral gavage on an every-other-day (once every two days) dosing schedule at various doses up to 160 mg/kg-its maximum tolerated dose in nude mice. In survival studies in Balb/C nude mice, the highest dose was reduced to 120 mg/kg as a result of the compromised animal condition due to lung and brain tumor implantation surgeries. | ||
|
0V278OKN9G
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY | |||
|
C92572
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY | NCIT | ||
|
DTXSID10657665
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY | |||
|
1061318-81-7
Created by
admin on Mon Mar 31 22:03:30 GMT 2025 , Edited by admin on Mon Mar 31 22:03:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
NCI Drug Dictionary: debio-0932
An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Debio 0932 specifically blocks Hsp90, thereby inhibiting its chaperone function and promoting the degradation of its client proteins, many of which are oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stabilization and degradation of many oncogenic signaling proteins. Check for active clinical trials using this agent. (NCI Thesaurus)
|
||
|
ACTIVE MOIETY |
Originator: Curis; Developer: Curis, Debiopharm; Class: 2 ring heterocyclic compound, Antineoplastic, Benzodioxole, Imidazole, Pyridine, Small molecule; Mechanism of Action: HSP90 heat-shock protein inhibitor; Available For Licensing: Yes for Cancer; Highest Development Phases: Phase I for Cancer, Discontinued for Lymphoma, Non-small cell lung cancer, Renal cancer, Solid tumours; Most Recent Events: 19 Jun 2015 CUDC 305 is available for licensing as of 19 Jun 2015. http://www.curis.com/, 11 May 2015 Phase-I clinical trials in Cancer in USA (PO), 01 Feb 2015 Curis re-acquires CUDC 305 from Debiopharm
|
